ASX 200 morning report – ResMed shares in focus
Drew Meredith, CFP
January 31, 2022
Australian investors had some respite on Friday, as volatility disappeared
ResMed Inc (ASX: RMD) is a United States based business that develops and manufactures medical devices to help people with sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed, which is short for Respiratory Medicine, was founded in 1989 by Dr Peter Farrell and now helps customers & patients in over 120 countries.
Australian investors had some respite on Friday, as volatility disappeared
Homegrown medical device company Resmed Inc (ASX: RMD) has updated
The S&P/ASX 200 (ASX:XJO) finished the week and the month
The Resmed CDI (ASX: RMD) share price has launched into
The S&P/ASX 200 (ASX:XJO) managed to push higher on Tuesday
The S&P/ASX 200 (ASX:XJO) suffered its worst day in months
The S&P/ASX 200 (ASX:XJO) overcame another 8% fall in the
The Resmed CDI (ASX: RMD) share price has been a
Global healthcare leader Resmed CDI (ASX: RMD) recorded a 14%
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
Here you go: A $50,000 per year passive income special report
Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.
Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.
Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.